JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Board Members and Executives Engage in Share Transactions
- Novo Nordisk Reports Strong 2024 Earnings Growth
- Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations
- Unusually active option classes on open February 5th
- Novo Nordisk Reports Robust 2024 Growth and Strategic Acquisitions